Thursday, August 27, 2015 11:34:57 PM
We know that the EbolaCide candidates did not fare well enough in cell culture to warrant animal testing, but we don't know why, do we? It's all speculation, just like just about every other "prediction" made here.
In my mind, it's more likely that the EbolaCides never made it into the endosome to interact with the uncapped Ebola glycoprotein that attaches to the Niemann Pick C1 receptor (and the EbolaCide), instead of the EbolaCide interacting with the virus but unable to destroy it because of its shape.
I could make something up, like EbolaCide didn't work because Diwan made them to fail on purpose, so he could steal the technology for himself (oh wait, did one of you already say that?)
Regarding "accurate" predictions from "inside" sources, when do the sources predict nanomicelle scale-up to be completed and material sent for tox testing?
What specifically are the problems with scale-up? Is it a lack of reproducibility of the process?
When and where do the sources predict MERS testing to take place?
How much material will be needed for HerpeCide testing? Will they partner it? Will HerpeCide leap-frog FluCide, since testing takes less material and FDA testing requirements are much less stringent for topical drugs versus IV ones?
As far as I can tell, the predictions made here all say one thing only: no nanoviricides will ever pass through toxicity testing phase of development; the company will go bankrupt; Diwan and Seymour planned this from the start, and are scamming all investors.
To me, these predictions are complete rubbish. Remotely possible, but rubbish none-the-less.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM